Ethyl Pyruvate Inhibits HMGB1 Phosphorylation and Release by Chelating Calcium
Overview
Molecular Biology
Authors
Affiliations
Ethyl pyruvate (EP), a simple aliphatic ester of pyruvic acid, has been shown to have antiinflammatory effects and to confer protective effects in various pathological conditions. Recently, a number of studies have reported EP inhibits high mobility group box 1 (HMGB1) secretion and suggest this might contribute to its antiinflammatory effect. Since EP is used in a calcium-containing balanced salt solution (Ringer solution), we wondered if EP directly chelates Ca(2+) and if it is related to the EP-mediated suppression of HMGB1 release. Calcium imaging assays revealed that EP significantly and dose-dependently suppressed high K(+)-induced transient [Ca(2+)]i surges in primary cortical neurons and, similarly, fluorometric assays showed that EP directly scavenges Ca(2+) as the peak of fluorescence emission intensities of Mag-Fura-2 (a low-affinity Ca(2+) indicator) was shifted in the presence of EP at concentrations of ≥7 mmol/L. Furthermore, EP markedly suppressed the A23187-induced intracellular Ca(2+) surge in BV2 cells and, under this condition, A23187-induced activations of Ca(2+)-mediated kinases (protein kinase Cα and calcium/calmodulin-dependent protein kinase IV), HMGB1 phosphorylation and subsequent secretion of HMGB1 also were suppressed. (A23187 is a calcium ionophore and BV2 cells are a microglia cell line.) Moreover, the above-mentioned EP-mediated effects were obtained independent of cell death or survival, which suggests that they are direct effects of EP. Together, these results indicate that EP directly chelates Ca(2+), and that it is, at least in part, responsible for the suppression of HMGB1 release by EP.
Targeting secretory autophagy in solid cancers: mechanisms, immune regulation and clinical insights.
Li X, Zhao H Exp Hematol Oncol. 2025; 14(1):12.
PMID: 39893499 PMC: 11786567. DOI: 10.1186/s40164-025-00603-0.
Emerging Roles of High-mobility Group Box-1 in Liver Disease.
Wang L, Dong Z, Zhang Y, Peng L J Clin Transl Hepatol. 2024; 12(12):1043-1056.
PMID: 39649031 PMC: 11622203. DOI: 10.14218/JCTH.2024.00317.
HMGB1 as an extracellular pro-inflammatory cytokine: Implications for drug-induced organic damage.
Yuan J, Guo L, Ma J, Zhang H, Xiao M, Li N Cell Biol Toxicol. 2024; 40(1):55.
PMID: 39008169 PMC: 11249443. DOI: 10.1007/s10565-024-09893-2.
High mobility group box-1: a potential therapeutic target for allergic rhinitis.
Wu S, Yu Y, Zheng Z, Cheng Q Eur J Med Res. 2023; 28(1):430.
PMID: 37828579 PMC: 10571310. DOI: 10.1186/s40001-023-01412-z.
Targeting HMGB1: A Potential Therapeutic Strategy for Chronic Kidney Disease.
Liu T, Li Q, Jin Q, Yang L, Mao H, Qu P Int J Biol Sci. 2023; 19(15):5020-5035.
PMID: 37781525 PMC: 10539693. DOI: 10.7150/ijbs.87964.